Optimal diagnosis and therapy of gastroesophageal reflux disease

Cite item

Full Text

About the authors

I O Ivanikov

V A Isakov

I V Maev


  1. Louis Harris & Associates. GERD in America, 1997: a two year follow-up study. New York: Louis Harris & Associates. 1997.
  2. El-Serag H. В., Sonnenberg A. Opposing time trends of peptic ulcer and reflux disease. Gut 1998. 43: 327-333.
  3. Johnston В. Т., Collins J. S., McFarland R. J. et al. Are oesophageal symptoms reflux-related? A study of different scoring systems in a cohort of patients with heartburn. Am. J. Gastroenterol. 1994; 89: 497-502.
  4. Dent J. Gastro-oesophageal reflux disease. Digestion 1998; 59: 433-445.
  5. Havelund Т., Lind Т., Wiklund I. et al. Quality of life in patients with heartburn but without esophagitis: Effects of treat--: ment with omeprazole. Am. J. Gastroenterol. 1999; 94: 1782- 1789.
  6. Locke G. R., Talley N. F., Fett S. L. et al. Prevalence and clinical spectrum of gastroesophageal reflux. Gastroenterology 1997; 112: 1448-1456.
  7. Rune S. J. Better definition of endoscopy-negative acid reflux disease. Aliment. Pharmacol. Ther. 1997; ll(suppl. 2): 79-80.
  8. Shi G., Tatum R. P., Joehl R. J., Kahrilas P. J. Esophageal sensitivity and symptom perception on gastroesophageal reflux disease. Curr. Gastroenterol. Rep. 1999; 1: 214-219.
  9. Lundell L. R., Dent J., Bennett J. R., Blum A. L. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999; 45: 172-180.
  10. An evidence-based appraisal of reflux disease management - the Genval Workshop Report. Gut 1999; 44(suppl. 2): SI- S16.
  11. GERD: evidence-based therapeutic strategies. AGA; 2002.
  12. van Pinxteren В., Numans M. E., Bonis P. A., Lau J. Shortterm treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastrooesophageal reflux diseaselike symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev. 2001; P. CD002095.
  13. Abelo A., Andersson Т. В., Antonsson M. et al. Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes. Drug Metab. Dispos. 2000; 28: 966-972.
  14. Andersson Т., К R. О., Bredberg E., Hassan-Alin M. Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole. Aliment. Pharmacol. Ther. 2001; 15: 1563-1569.
  15. Caro J. J., Salas M., Ward A. Healing and relapse rates in gastroesophageal reflux disease treated with the newer protonpump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials. Clin. Ther. 2001; 23: 998- 1017.
  16. Delchier J. C., Cohen G., Humphries T. J. Rabeprazole, 20 mg once daily or 10 mg twice daily, is equivalent to omeprazole, 20 mg once daily, in the healing of erosive gastrooesophageal reflux disease. Scand. J. Gastroenterol. 2000; 35: 1245-1250.
  17. Edwards S. J., Lind Т., Lundell L. Systematic review of proton pump inhibitors for the acute treatment of reflux oesophagitis. Aliment. Pharmacol. Ther. 2001; 15: 1729-1736.
  18. Vakil N. Review article: esomeprazole, 40 mg once daily, compared with lansoprazole, 30 mg once daily, in healing and symptom resolution of erosive oesophagitis. Aliment. Pharmacol. Ther. 2003; 17(suppl. 1): 21-23.

Copyright (c) 2004 Ivanikov I.O., Isakov V.A., Maev I.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru


© 2018-2021 "Consilium Medicum" Publishing house

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies